AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3083146 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term MF chemotherapy (mitomycin C, 0.04 mg/kg + 5-fluorouracil, 5.0 mg/kg X 6, IVr)
Number of subjects: 0
Study 3083146 — intervention group
Group type: COMPARATOR
Intervention: Long-term carmofur chemotherapy (Mifurol, 6-12 mg/kg/day over 12 weeks, PO)
Number of subjects: 0
Study 3083146 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmofur maintenance therapy
Number of subjects: 0
Study 30171784 — intervention group
Group type: EXPERIMENTAL
Intervention: PPC (personal protective clothing)
Number of subjects: 34
Study 30171784 — intervention group
Group type: EXPERIMENTAL
Intervention: SCBA (full self‐contained breathing apparatus)
Number of subjects: 34
Study 30171784 — intervention group
Group type: EXPERIMENTAL
Intervention: SCBAc (only the cylinder of the self‐contained breathing apparatus)
Number of subjects: 34
Study 27494299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis (20 mg once daily)
Number of subjects: 0
Study 24818952 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 10074
Study 24818952 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10074
Study 22402737 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of at least 5% of baseline weight
Number of subjects: 383
Study 22402737 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of 5-10% of baseline weight
Number of subjects: 383
Study 22402737 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of >10% of baseline weight
Number of subjects: 383
Study 22402737 — intervention group
Group type: EXPERIMENTAL
Intervention: No weight loss
Number of subjects: 383
Study 22402737 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall weight loss effect
Number of subjects: 383
Study 19782346 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg recombinant hCG
Number of subjects: 0
Study 19782346 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg recombinant hCG
Number of subjects: 0
Study 18443051 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach trapeziectomy
Number of subjects: 41
Study 18443051 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach trapeziectomy
Number of subjects: 41
Study 15832879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention developed specifically for Latino gay and bisexual men, based on empowerment theory.
Number of subjects: 180
Study 15832879 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 180
Study 12574571 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Supported Discharge (ESD)
Number of subjects: 0
Study 12574571 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study 10579057 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy consisting of metronidazole, bismuth subcitrate, and amoxicillin
Number of subjects: 85
Study 10579057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 8930145 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (20 mg)
Number of subjects: 10
Study 8930145 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (30 mg)
Number of subjects: 10
Study 8930145 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (10 mg)
Number of subjects: 10
Study 8930145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 10
Study 1811040 — intervention group
Group type: EXPERIMENTAL
Intervention: Kurer Fin Lock Anchor
Number of subjects: 25
Study 1811040 — intervention group
Group type: EXPERIMENTAL
Intervention: Radix Anchor
Number of subjects: 25
Study 1811040 — intervention group
Group type: COMPARATOR
Intervention: Para-Post Plus (control post)
Number of subjects: 25
Study 1811040 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexi-Post
Number of subjects: 25
Study 1811040 — intervention group
Group type: EXPERIMENTAL
Intervention: Vlock post
Number of subjects: 25
Study 3912355 — intervention group
Group type: EXPERIMENTAL
Intervention: 34.5 Gy of radiotherapy (in 3 weeks) followed by surgery
Number of subjects: 466
Study 3912355 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 466
Study 31898551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive ergonomics intervention
Number of subjects: 1169
Study 31898551 — intervention group
Group type: COMPARATOR
Intervention: Active control group (recovery supporting)
Number of subjects: 1169
Study 31898551 — intervention group
Group type: COMPARATOR
Intervention: Passive control group (no intervention)
Number of subjects: 1169
Study 29994874 — intervention group
Group type: EXPERIMENTAL
Intervention: paritaprevir/ombitasvir/ritonavir/dasabuvir/ribavirin (RBV) for 12 weeks
Number of subjects: 96
Study 29994874 — intervention group
Group type: COMPARATOR
Intervention: ledipasvir/sofosbuvir (SOF)/RBV for 12 weeks
Number of subjects: 96
Study 26771445 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (80 mg QD)
Number of subjects: 109
Study 26771445 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (300 mg QD)
Number of subjects: 109
Study 25376884 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-protein drink (20 g daily plus 20 g after each PRT session) and vitamin D supplements (2000 IU/day)
Number of subjects: 200
Study 25376884 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) based on the Lift for Life® programme
Number of subjects: 200
Study 25376884 — intervention group
Group type: COMPARATOR
Intervention: No additional powder and supplements (control group)
Number of subjects: 200
Study 22497897 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter fluency test
Number of subjects: 0
Study 20545392 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 30 mg b.i.d. (0900 and 1300)
Number of subjects: 12
Study 20545392 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 12
Study 20545392 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 30 mg b.i.d.
Number of subjects: 12
Study 18635428 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet, restricted-calorie
Number of subjects: 322
Study 18635428 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet, restricted-calorie
Number of subjects: 322
Study 18635428 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet, non-restricted-calorie
Number of subjects: 322
Study 17207282 — intervention group
Group type: EXPERIMENTAL
Intervention: Amaranth oil application
Number of subjects: 0
Study 14973337 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm raising and lowering at 3 different speeds
Number of subjects: 8
Study 11203744 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual cycle phases (menstrual, follicular, periovulatory, luteal)
Number of subjects: 18
Study 9443524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with risperidone
Number of subjects: 43
Study 9443524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment without risperidone
Number of subjects: 43
Study 9443524 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 43
Study 9443524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment groups (both with and without risperidone)
Number of subjects: 43
Study 8407738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, three times a day)
Number of subjects: 120
Study 8407738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3812051 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% expanded tobacco
Number of subjects: 24
Study 3812051 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% expanded tobacco
Number of subjects: 24
Study 3812051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both blends
Number of subjects: 24
Study 30731492 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 3874
Study 30731492 — intervention group
Group type: EXPERIMENTAL
Intervention: High SAMe-TT2-R2 score
Number of subjects: 3874
Study 30731492 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe-TT2-R2 score
Number of subjects: 3874
Study 30731492 — intervention group
Group type: EXPERIMENTAL
Intervention: High vs. low SAMe-TT2-R2 score
Number of subjects: 3874
Study 28203684 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ticagrelor tablets given orally
Number of subjects: 9
Study 28203684 — intervention group
Group type: COMPARATOR
Intervention: Crushed ticagrelor tablets given sublingually
Number of subjects: 9
Study 25440643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (1.8 U/h)
Number of subjects: 92
Study 25440643 — intervention group
Group type: COMPARATOR
Intervention: Control (1.8 mL/h of normal saline)
Number of subjects: 92
Study 23535252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 57
Study 23535252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 21636015 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of glucose
Number of subjects: 56
Study 21636015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 21636015 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated baseline blood glucose
Number of subjects: 56
Study 19794940 — intervention group
Group type: COMPARATOR
Intervention: MLG treatment
Number of subjects: 60
Study 19794940 — intervention group
Group type: EXPERIMENTAL
Intervention: MLG+IVTA treatment
Number of subjects: 60
Study 19794940 — intervention group
Group type: COMPARATOR
Intervention: IVTA treatment
Number of subjects: 60
Study 16920243 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 commercially available and authority‐approved enzymes used in the food industry
Number of subjects: 400
Study 16920243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 12899896 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR)
Number of subjects: 22
Study 12899896 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 22
Study 10853908 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative reduction followed by splinting the elbow in a flexed and supinated position for 2 days
Number of subjects: 64
Study 10853908 — intervention group
Group type: COMPARATOR
Intervention: Manipulative reduction only
Number of subjects: 64
Study 9089856 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 1 mg plus sufentanil 5 micrograms plus epinephrine 25 micrograms
Number of subjects: 42
Study 9089856 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 1 mg plus sufentanil 5 micrograms
Number of subjects: 42
Study 8224289 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bupivacaine
Number of subjects: 36
Study 8224289 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 36
Study 3544346 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operated patients with bilateral MCA trunk occlusion
Number of subjects: 9
Study 31953725 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic radical gastrectomy (3D-LG)
Number of subjects: 401
Study 31953725 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopic radical gastrectomy (2D-LG)
Number of subjects: 401
Study 31953725 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-LG
Number of subjects: 401
Study 31953725 — intervention group
Group type: COMPARATOR
Intervention: 2D-LG
Number of subjects: 401
Study 31953725 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 401
Study 31953725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor diameter, pTNM stage, lymphovascular invasion
Number of subjects: 401
Study 31182766 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib treatment
Number of subjects: 1130
Study 29256981 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser trephination
Number of subjects: 134
Study 29256981 — intervention group
Group type: COMPARATOR
Intervention: Motor trephination (control)
Number of subjects: 134
Study 26976495 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (20 mg/kg loading dose followed by 5 mg/kg daily maintenance until the 10th day of life)
Number of subjects: 52
Study 26976495 — intervention group
Group type: COMPARATOR
Intervention: Control (no caffeine treatment)
Number of subjects: 52
Study 25029955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.25 mg
Number of subjects: 145
Study 25029955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.5 mg
Number of subjects: 145
Study 25029955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 145
Study 25029955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 145
Study 25029955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 23146638 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cartridges of 2% lidocaine with 1:100,000 epinephrine via the IAN block
Number of subjects: 124
Study 23146638 — intervention group
Group type: EXPERIMENTAL
Intervention: Red-haired women with 2 RHC alleles
Number of subjects: 124
Study 23146638 — intervention group
Group type: COMPARATOR
Intervention: Women with dark hair or women with 0 RHC alleles
Number of subjects: 124
Study 20809193 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy for noisiform tinnitus
Number of subjects: 23
Study 20809193 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging examinations
Number of subjects: 23
Study 20809193 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysiological measurements
Number of subjects: 23
Study 18055956 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs plus CBT
Number of subjects: 208
Study 18055956 — intervention group
Group type: COMPARATOR
Intervention: SSRIs alone
Number of subjects: 208
Study 16338568 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional counseling about potential intraoperative visual experience
Number of subjects: 219
Study 16338568 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative counseling only (no additional counseling)
Number of subjects: 219
Study 11806215 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 257
Study 11806215 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 257
Study 9552064 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 16 microg/kg
Number of subjects: 44
Study 9552064 — intervention group
Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (HDCTX) 6 g/m2 plus G-CSF 5 microg/kg
Number of subjects: 44
Study 7939138 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at an initial dose of 15 mg/week
Number of subjects: 185
Study 7939138 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at an initial dose of 25 mg/week
Number of subjects: 185
Study 3373405 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg) administered intravenously every 24 hours for a total of three doses
Number of subjects: 36
Study 3373405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution) administered intravenously every 24 hours for a total of three doses
Number of subjects: 36
Study 3373405 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment
Number of subjects: 36
Study 3373405 — intervention group
Group type: COMPARATOR
Intervention: Saline solution treatment
Number of subjects: 36
Study 31849123 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine (LC) 2 g for 8 weeks
Number of subjects: 52
Study 29844808 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-reflux treatment
Number of subjects: 136
Study 26634616 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 77
Study 26634616 — intervention group
Group type: COMPARATOR
Intervention: Rumination
Number of subjects: 77
Study 26634616 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 77
Study 25330169 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and telephone-guided access to community support
Number of subjects: 436
Study 25330169 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 436
Study 22331759 — intervention group
Group type: EXPERIMENTAL
Intervention: Test A (Glycomet SR)
Number of subjects: 18
Study 22331759 — intervention group
Group type: EXPERIMENTAL
Intervention: Test B (Bigomet SR)
Number of subjects: 18
Study 22331759 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 18
Study 20219962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplements (1200 IU/d)
Number of subjects: 334
Study 20219962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 17617938 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil
Number of subjects: 30
Study 17617938 — intervention group
Group type: EXPERIMENTAL
Intervention: Common olive oil
Number of subjects: 30
Study 17617938 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined olive oil
Number of subjects: 30
Study 17617938 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oils rich in phenolic compounds
Number of subjects: 30
Study 17617938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15613438 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium administration (1 g calcium gluconate)
Number of subjects: 30
Study 15613438 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptone loading test (10 g protein hydrolyzed)
Number of subjects: 30
Study 11849571 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.5 mg x kg(‐1) mixed with sodium citrate
Number of subjects: 40
Study 11849571 — intervention group
Group type: COMPARATOR
Intervention: midazolam 0.5 mg x kg(‐1) mixed with Hawaiian fruit punch
Number of subjects: 40
Study 10756609 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemarketing
Number of subjects: 614
Study 10756609 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal marketing
Number of subjects: 614
Study 10756609 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal marketing
Number of subjects: 614
Study 8873835 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanic acid (1.2 g i.v. every 8 hours for 3-4 days, followed by 625 mg orally every 8 hours until labor)
Number of subjects: 75
Study 8873835 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanic acid
Number of subjects: 75
Study 1824374 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection pen system (Nordiject) for administration of B-hGH (Norditropin)
Number of subjects: 27
Study 1824374 — intervention group
Group type: COMPARATOR
Intervention: Syringe (4 IU/ml)
Number of subjects: 27
Study 1824374 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection pen (Nordiject) (12 IU/ml)
Number of subjects: 27
Study 6188895 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 22
Study 6188895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30629717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified rice (FFR)
Number of subjects: 800
Study 30629717 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified rice (non‐FFR)
Number of subjects: 800
Study 30567952 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-item Morisky Medication Adherence Scale (MMAS-9)
Number of subjects: 0
Study 27909034 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus formal Advance Care Planning (ACP) intervention
Number of subjects: 210
Study 27909034 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 210
Study 27909034 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus formal ACP intervention
Number of subjects: 210
Study 25166719 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5442 (2.5, 5, 7.5, 10, or 15 mg)
Number of subjects: 383
Study 25166719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 25166719 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5442 (higher doses)
Number of subjects: 383
Study 23020659 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Chips (PerioC)
Number of subjects: 60
Study 23020659 — intervention group
Group type: COMPARATOR
Intervention: Matrix Chips (MatrixC)
Number of subjects: 60
Study 18773914 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially sweetened solutions (aspartame concentrations of 0, 0.01, 0.03, 0.08, and 0.28%)
Number of subjects: 21
Study 18773914 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 21
Study 17635944 — intervention group
Group type: EXPERIMENTAL
Intervention: Water deprivation for 28 hours
Number of subjects: 24
Study 17635944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion combined with thirsting for 17 hours
Number of subjects: 24
Study 17635944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic saline infusion with iv desmopressin during free water intake
Number of subjects: 24
Study 15832114 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet (normal breakfast followed by low-residue lunch)
Number of subjects: 200
Study 15832114 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (light breakfast followed by clear liquids)
Number of subjects: 200
Study 15832114 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet
Number of subjects: 200
Study 11079257 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day simvastatin and 2 mg folic acid/0.8 mg vitamin B12 daily (combination group)
Number of subjects: 141
Study 11079257 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day simvastatin and placebo vitamins (simvastatin alone group)
Number of subjects: 141
Study 11079257 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg folic acid/0.8 mg vitamin B12 daily and placebo simvastatin (vitamins alone group)
Number of subjects: 141
Study 9145970 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis prior to SWL
Number of subjects: 1482
Study 9145970 — intervention group
Group type: COMPARATOR
Intervention: Placebo/no treatment
Number of subjects: 1482